JWJian Wu

Jian Wu

*This is an algorithmically generated author record based on publicly available information.

Jian Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrative genomic analysis reveals cancer-associated mutations in patients with ophthalmic tumors

    by Fengjiao Zhu, Pengpeng Wang, Zhiyuan Zhang, Chunlei Yao, Yijie Wang, Juan Ye, Jian Wu

    Objective: Apart from the role of the retinoblastoma gene, the genomic events associated with poor outcomes in patients with ophthalmic tumors are poorly understood. Methods: We retrospectively analyzed 48 patients with six types of ophthalmic tumors. We searched for high-frequency mutated genes and susceptibility genes in these patients using combined exome and transcriptome analysis. Results: We identified four clearly causative genes ( TP53, PTCH1, SMO, BAP1). Susceptibility gene analysis identified hotspot genes, including RUNX1, APC, IDH2, and BRCA2, and high-frequency gene analysis identified several genes, including TP53, TTN, and MUC16. Transcriptome analysis identified 5868 differentially expressed genes, of which TOP2A and ZWINT were upregulated in all samples, while CFD, ELANE, HBA1, and HBB were downregulated. Kyoto Encyclopedia of Genes and Genomes enrichment analysis indicated that the phosphoinositide 3-kinase (PI3K)-Akt and Transcriptional misregulation in cancer signaling pathways may be involved in ophthalmic tumorigenesis. Conclusions: TP53 is clearly involved in ophthalmic tumorigenesis, especially in basal cell carcinoma, and the PI3K-Akt signaling pathway may be an essential pathway involved in ophthalmic tumorigenesis. RUNX1, SMO, TOP2A, and ZWINT are also highly likely to be involved in ophthalmic tumorigenesis, but further functional experiments are needed to verify the mechanisms of these genes in regulating tumorigenesis.


  • Open Access

    Integrative genomic analysis reveals cancer-associated mutations at the diagnosis of cancer in patients with ocular tumors

    by Fengjiao Zhu, Pengpeng Wang, Zhiyuan Zhang, Chunlei Yao, Jie Ii, Juan Ye, Jian Wu

    The genomic events associated with poor outcomes in other ocular tumors are poorly understood, except for the in-depth study of the retinoblastoma Rb gene. We investigated 48 patients with ocular tumors, using three types of samples - cancerous tissue, paraneoplastic tissue, and peripheral blood. We employed combined exome and transcriptome analysis to search for high-frequency mutated genes and susceptibility genes in ocular tumors. Our exon sequencing analysis identified four clear causative genes (TP53, PTCH1, SMO, BAP1), most of which were associated with basal cell carcinoma. Two mutations in BAP1 were clearly associated with choroidal melanoma, and no clear causative loci were found in other cancer types. Our susceptibility gene analysis identified hotspot genes such as RUNX1, APC, IDH2, and BRCA2. High-frequency gene analysis identified TP53, TTN, and MUC16 genes, among others. Transcriptome analysis identified TOP2A and ZWINT genes were upregulated in all samples, while CFD, ELANE, HBA1, and HBB were downregulated. Our KEGG enrichment analysis indicated that the PI3K-Akt signaling pathway and transcriptional misregulation in cancer may be involved in the process of ocular tumorigenesis. We found that TP53 is clearly involved in ocular tumorigenesis, especially in basal cell carcinoma, and its PI3K-Akt signaling pathway may be an essential pathway involved in ocular tumorigenesis. Additionally, RUNX1, SMO, TOP2A, and ZWINT are highly likely to be involved in ocular tumorigenesis, and subsequent functional experiments can be carried out to verify the mechanisms of these genes in regulating tumorigenesis.

  • Open Access

    T-Cell Receptor β Chain and B-Cell Receptor Repertoires in Chronic Hepatitis B Patients with Coexisting HBsAg and Anti-HBs

    by Qiao Zhan, Le Chang, Jian Wu, Zhiyuan Zhang, Jinghang Xu, Yanyan Yu, Zhenru Feng, Zheng Zeng

    Antibodies in response to antigens are related to the immune repertoire of T- and B-cell receptors. However, some patients with chronic hepatitis B (CHB) have coexisting HBsAg and anti-HBsAg antibodies (anti-HBs) that cannot neutralize HBV. We attempted to investigate the repertoires that produce this response in CHB patients. The T-cell receptor β chain (TRB) and B-cell receptor (BCR) repertoires of peripheral blood genomic DNA were analyzed using MiXCR. T-cell receptor (TCR) cluster analysis was carried out by clusTCR, and motifs prediction was selected by Multiple Em for Motif Elicitation (MEME). A total of 76 subjects were enrolled, including 26 HBsAg and anti-HBs coexisting patients with CHB (DP group), 25 anti-HBs single-positive healthy people (SP group), and 25 CHB patients (CHB group). The clone length of BCR in 39, 90 was significantly different among these groups (p = 0.005, 0.036). The motif “CASSLG” in the DP group was significantly higher than SP and CHB groups and may relate to coexistence, and the motif “GAGPLT” was only shown in the SP group and may relate to anti-HB expression. These provide important insights into vaccine development and CHB treatment.


  • Open Access

    i2APP: A Two-Step Machine Learning Framework For Antiparasitic Peptides Identification

    by Minchao Jiang, Renfeng Zhang, Yixiao Xia, Gangyong Jia, Yuyu Yin, Pu Wang, Jian Wu, Ruiquan Ge

    Parasites can cause enormous damage to their hosts. Studies have shown that antiparasitic peptides can inhibit the growth and development of parasites and even kill them. Because traditional biological methods to determine the activity of antiparasitic peptides are time-consuming and costly, a method for large-scale prediction of antiparasitic peptides is urgently needed. We propose a computational approach called i2APP that can efficiently identify APPs using a two-step machine learning (ML) framework. First, in order to solve the imbalance of positive and negative samples in the training set, a random under sampling method is used to generate a balanced training data set. Then, the physical and chemical features and terminus-based features are extracted, and the first classification is performed by Light Gradient Boosting Machine (LGBM) and Support Vector Machine (SVM) to obtain 264-dimensional higher level features. These features are selected by Maximal Information Coefficient (MIC) and the features with the big MIC values are retained. Finally, the SVM algorithm is used for the second classification in the optimized feature space. Thus the prediction model i2APP is fully constructed. On independent datasets, the accuracy and AUC of i2APP are 0.913 and 0.935, respectively, which are better than the state-of-arts methods. The key idea of the proposed method is that multi-level features are extracted from peptide sequences and the higher-level features can distinguish well the APPs and non-APPs.


  • Open Access

    Mutation analysis of Chinese sporadic congenital sideroblastic anemia by targeted capture sequencing

    by Wenbin An, Jingliao Zhang, Lixian Chang, Yingchi Zhang, Yang Wan, Yuanyuan Ren, Deyun Niu, Jian Wu, Xiaofan Zhu, Ye Guo

    Congenital sideroblastic anemias (CSAs) comprise a group of heterogenous genetic diseases that are caused by the mutation of various genes involved in heme biosynthesis, iron-sulfur cluster biogenesis, or mitochondrial solute transport or metabolism. However, approximately 40 % of patients with CSA have not been found to have pathogenic gene mutations. In this study, we systematically analyzed the mutation profile in 10 Chinese patients with sporadic CSA. We performed targeted deep sequencing analysis in ten patients with CSA using a panel of 417 genes that included known CSA-related genes. Mitochondrial genomes were analyzed using next-generation sequencing with a mitochondria enrichment kit and the HiSeq2000 sequencing platform. The results were confirmed by Sanger sequencing. The ALAS2 mutation was detected in one patient. SLC25A38 mutations were detected in three patients, including three novel mutations. Mitochondrial DNA deletions were detected in two patients. No disease-causing mutations were detected in four patients. To our knowledge, the pyridoxine-effective mutation C471Y of ALAS2, the compound heterozygous mutation W87X, I143Pfs146X, and the homozygous mutation R134C of SLC25A38 were found for the first time. Our findings add to the number of reported cases of this rare disease and to the CSA pathogenic mutation database. Our findings expand the phenotypic profile of mitochondrial DNA deletion mutations. This work also demonstrates the application of a congenital blood disease assay and targeted capture sequencing for the genetic screening analysis and diagnosis of heterogenous genetic CSA.